Cargando…

Establishment and characterization of the gemcitabine-resistant human pancreatic cancer cell line SW1990/gemcitabine

Due to its rapid progression, metastasis and resistance to chemotherapy, pancreatic cancer is one of the most malignant tumor types to affect the digestive system. Gemcitabine chemotherapy is typically the first choice of treatment for advanced pancreatic cancer; however, chemoresistance is a major...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Yue, Ding, Fei, Gao, Meng, Jia, Yi Fu, Ren, Le
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676397/ https://www.ncbi.nlm.nih.gov/pubmed/31452783 http://dx.doi.org/10.3892/ol.2019.10627

Ejemplares similares

Gemcitabine Conjugated Chitosan and Double Antibodies (Abc-GC-Gemcitabine Nanoparticles) Enhanced Cytoplasmic Uptake of Gemcitabine and Inhibit Proliferation and Metastasis In Human SW1990 Pancreatic Cancer Cells
por: Xiao, Jun, et al.
Publicado: (2017)

Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine
por: Varamo, Chiara, et al.
Publicado: (2019)

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
por: Melisi, Davide, et al.
Publicado: (2018)

Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer
por: Yang, Jianhui, et al.
Publicado: (2021)

Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
por: Lim, Jae Yun, et al.
Publicado: (2015)

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
por: Chiorean, E Gabriela, et al.
Publicado: (2016)

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
por: Chiorean, E Gabriela, et al.
Publicado: (2016)

Increased mitochondria are responsible for the acquisition of gemcitabine resistance in pancreatic cancer cell lines
por: Masuo, Hitoshi, et al.
Publicado: (2023)

Nardoguaianone L Isolated from Nardostachys jatamansi Improved the Effect of Gemcitabine Chemotherapy via Regulating AGE Signaling Pathway in SW1990 Cells
por: Zheng, Yi-Dan, et al.
Publicado: (2022)

Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer
por: Mahajan, Ujjwal M, et al.
Publicado: (2019)

Astaxanthin inhibits gemcitabine-resistant human pancreatic cancer progression through EMT inhibition and gemcitabine resensitization
por: Yan, Tao, et al.
Publicado: (2017)

Pancreatic Cancer Chemoresistance to Gemcitabine
por: Amrutkar, Manoj, et al.
Publicado: (2017)

Establishment of a human primary pancreatic cancer mouse model to examine and investigate gemcitabine resistance
por: Zhang, Ya-Jing, et al.
Publicado: (2017)

Identification of chemoresistance‐related mRNAs based on gemcitabine‐resistant pancreatic cancer cell lines
por: Zhou, Jiarong, et al.
Publicado: (2019)

Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression
por: Guo, Zhongyi, et al.
Publicado: (2018)

Correction: Clusterin confers gemcitabine resistance in pancreatic cancer
por: Chen, Qingfeng, et al.
Publicado: (2013)

Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway
por: Zhou, Yunjiang, et al.
Publicado: (2019)

Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma
por: Shao, Feng, et al.
Publicado: (2018)

Cytotoxicity of gemcitabine-loaded thermosensitive liposomes in pancreatic cancer cell lines
por: Affram, Kevin, et al.
Publicado: (2015)

Metformin Inhibits Gemcitabine Induced Apoptosis in Pancreatic Cancer Cell Lines
por: Zechner, Dietmar, et al.
Publicado: (2017)

Cytosolic 5′-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites
por: Patzak, Melanie S., et al.
Publicado: (2019)

The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence
por: Prejac, Juraj, et al.
Publicado: (2022)

Gemcitabine Resistance in Pancreatic Ductal Carcinoma Cell Lines Stems from Reprogramming of Energy Metabolism
por: Fujiwara-Tani, Rina, et al.
Publicado: (2022)

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells
por: Nakano, Y, et al.
Publicado: (2007)

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
por: Demols, A, et al.
Publicado: (2006)

Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
por: Ouyang, Guoqing, et al.
Publicado: (2016)

Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer
por: Ma, Yang-Yang, et al.
Publicado: (2020)

Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma
por: Liu, Kaidong, et al.
Publicado: (2022)

The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine
por: Hornick, John R, et al.
Publicado: (2010)

Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
por: Wilbur, H. Catherine, et al.
Publicado: (2023)

GATA1 Promotes Gemcitabine Resistance in Pancreatic Cancer through Antiapoptotic Pathway
por: Chang, Zhenyu, et al.
Publicado: (2019)

Inhibitory effect of baicalein combined with gemcitabine in human pancreatic cancer cell lines
por: Li, Zhenlei, et al.
Publicado: (2018)

The role of ferroptosis regulators in the prognosis, immune activity and gemcitabine resistance of pancreatic cancer
por: Tang, Rong, et al.
Publicado: (2020)

Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database
por: Shin, Sangjin, et al.
Publicado: (2016)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
por: de Jong, Evelien J. M., et al.
Publicado: (2021)

Gemcitabine-Loaded Albumin Nanoparticle Exerts An Antitumor Effect on Gemcitabine-Resistant Pancreatic Cancer Cells Induced by MDR1 and MRP1 Overexpression in Vitro
por: Kong, Lei, et al.
Publicado: (2022)

The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer
por: Jia, Yanfei, et al.
Publicado: (2018)

Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells
por: Lu, Jun, et al.
Publicado: (2023)

Novel Strategy with Gemcitabine for Advanced Pancreatic Cancer
por: Komori, Shuji, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_knut8q9n9tmaku9ku4907of2vi